1354787-71-5|DC41SMe|DC41SMe|No data available-范德生物科技公司

DC41SMe

NMR下载 COA and HPLC MSDS下载
names：
DC41SMe
CAS号：
1354787-71-5
MDL Number： No data available
MF(分子式)： C38H36ClN5O4S2 MW(分子量)： 726.31
EINECS:No data available Reaxys Number:No data available
Pubchem ID:No data available Brand:BIOFOUNT

DC41SMe(1354787-71-5)是DC1衍生物，在Ramos，Namalwa和HL60 / s细胞中表现出细胞毒性，IC50范围为18-25 pM。 DC1是CC-1065的简化类似物，是细胞毒性DNA烷基化剂的抗体偶联物，用于靶向治疗癌症。

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)
YZM000924-250mg	250mg	>95%	¥ 0.00	¥ 0.00		Backorder	- +	¥ 0.00
YZM000924-100mg	100mg	>95%	¥ 0.00	¥ 0.00		Backorder	- +	¥ 0.00

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	DC41SMe(1354787-71-5)
英文别名	DC41SMe,1354787-71-5
CAS号	1354787-71-5
SMILES	O=C(C(N1)=CC2=C1C=CC(NC(CCC(SSC)(C)C)=O)=C2)NC3=CC4=C(NC(C(N5C[C@@H](CCl)C6=C5C=C(O)C7=CC=CC=C67)=O)=C4)C=C3
Inchi	No data available
InchiKey	No data available
分子式 Formula	C38H36ClN5O4S2
分子量 Molecular Weight	726.31
闪点 FP	No data available
熔点 Melting point	No data available
沸点 Boiling point	No data available
Polarizability极化度	No data available
密度 Density	No data available
蒸汽压 Vapor Pressure	No data available
溶解度Solubility
性状	Solid
储藏条件 Storage conditions	请根据产品建议的存储条件进行存储,Please store the product under the recommended condition sin the description.

DC41SMe(1354787-71-5)实验注意事项：
1.实验前需戴好防护眼镜，穿戴防护服和口罩，佩戴手套，避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生，必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储，并交于专业生物废气物处理公司处理，以免造成环境污染

DC41SMe(1354787-71-5) Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tag:DC41SMe(1354787-71-5),DC41SMe试剂,DC41SMe抑制剂,DC41SMe的纯度,DC41SMe的作用,DC41SMe的使用,DC41SMe的合成,DC41SMe的MSDS,DC41SMe的COA,DC41SMe的生产,DC41SMe的效果,DC41SMe的注意事项,DC41SMe的外观,DC41SMe的溶解度

产品说明	DC41SMe(1354787-71-5)是一种有效的 DC1 衍生物，对 Ramos、Namalwa 和 HL60/s 细胞显示细胞毒性.
Introduction	DC41SMe(1354787-71-5), a DC1 derivative, shows cytotoxicity in Ramos, Namalwa, and HL60/s cells with IC50s ranging from 18-25 pM.
Application1
Application2
Application3

1.Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen
Kovtun YV, Audette CA, Ye Y, Xie H, Ruberti MF, Phinney SJ, Leece BA, Chittenden T, Blättler WA, Goldmacher VS.
Conjugates of the anti-CanAg humanized monoclonal antibody huC242 with the microtubule-formation inhibitor DM1 (a maytansinoid), or with the DNA alkylator DC1 (a CC1065 analogue), have been evaluated for their ability to eradicate mixed cell populations formed from CanAg-positive and CanAg-negative cells in culture and in xenograft tumors in mice. We found that in culture, conjugates of either drug killed not only the target antigen-positive cells but also the neighboring antigen-negative cells. Furthermore, we showed that, in vivo, these conjugates were effective in eradicating tumors containing both antigen-positive and antigen-negative cells. The presence of antigen-positive cells was required for this killing of bystander cells. This target cell-activated killing of bystander cells was dependent on the nature of the linker between the antibody and the drug. Conjugates linked via a reducible disulfide bond were capable of exerting the bystander effect whereas equally potent conjugates linked via a nonreducible thioether bond were not. Our data offer a rationale for developing optimally constructed antibody-drug conjugates for treating tumors that express the target antigen either in a homogeneous or heterogeneous manner.

警示图
危险性	warning
危险性警示	Not available
安全声明	H303吞入可能有害+H313皮肤接触可能有害+H2413吸入可能对身体有害
安全防护	P264处理后彻底清洗+P280戴防护手套/穿防护服/戴防护眼罩/戴防护面具+P305如果进入眼睛+P351用水小心冲洗几分钟+P338取出隐形眼镜（如果有）并且易于操作,继续冲洗+P337如果眼睛刺激持续+P2393获得医疗建议/护理
备注	实验过程中防止吸入、食入，做好安全防护

Synthesis and biological evaluation of antibody conjugates of phosphate prodrugs of cytotoxic DNA alkylators for the targeted treatment of cancer
Zhao RY, Erickson HK, Leece BA, Reid EE, Goldmacher VS, Lambert JM, Chari RV.
The synthesis and biological evaluation of phosphate prodrugs of analogues of 1 (CC-1065) and their conjugates with antibodies are described. The phosphate group on the 1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (CBI) portion of the compounds confers enhanced solubility and stability in aqueous solutions. In the presence of phosphatases, these compounds convert into active DNA-alkylating agents. The synthesis of the prodrugs was achieved sequentially through coupling of CBI with a bis-indolyl moiety, followed by attachment of a thiol-containing linker, and conversion of the hydroxyl group of CBI into a phosphate prodrug. The linkers incorporated into the prodrugs enable conjugation to an antibody via either a stable disulfide or thioether bond, in aqueous buffer solutions containing as little as 5% organic cosolvent, resulting in exclusively monomeric and stable antibody-cytotoxic prodrug conjugates. Two disulfide-containing linkers differing in the degree of steric hindrance were used in antibody conjugates to test the effect of different rates of intracellular disulfide cleavage and effector release on biological activity. The prodrugs can be converted to the active cytotoxic compounds through the action of endogenous phosphatases. Antibody-prodrug conjugates displayed potent antigen-selective cytotoxic activity in vitro and antitumor activity in vivo.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开